Our Faculty

Michael WN Deininger, M.D., Ph.D.
Section Head, Center for Hematologic Malignancies, Non-Transplant
Associate Professor

Specialty: Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myeloproliferative Disorders

Clinic Phone: 503-494-5058
Lab Phone: 503-494-1603
E-mail: deininge@ohsu.edu

Born in Germany 1963. Gymnasium in Hof/Saale. Best final exam in the State of Bavaria. Scholar of the German Scholarship Foundation. Study of Medicine at the University of Wuerzburg. Electives in the UK, Austria, US, Poland and Russia. 1994 MD thesis on myelodysplastic syndromes. 2000 PhD in leukemia biology from Imperial College, London. 2002 Assistant Professor and 2007 Associate Professor at Oregon Health & and Science University. 2004-2006 Scholar of the American Society of Hematology. 2007 Head, Hematologic Malignancies Section, OHSU.

• Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E, Berger R, Clark JJ, Willis SG, Nguyen KT, Flores NJ, Estey E, Gattermann N, Armstrong S, Look AT, Griffin JD, Bernard OA, Heinrich MC, Gilliland DG, Druker B, Deininger MW, The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood, 2005. 106(10): p. 3377-9.
• Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D, Stoffregen EP, McWeeney S, Kovacs I, Park B, Druker BJ, Deininger MW, High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood, 2005. 106(6): p. 2128-37.
• Griswold IJ, Mac Partlin M, Bumm T, Goss VL, O Hare T, Lee KA, Corbin AS, Stoffregen EP, Johnson KJ, Moseson EM, Wood LJ, Polakiewicz RD, Druker BJ, Deininger MW, Transformation potency of kinase domain mutants of Bcr-Abl. Mol. Cell Biol., 2006. 26(16): p. 6082-93.
• Bradeen HA, Eide C, O'Hare T, Johnson KJ, Willis SG, Lee FY, Druker BJ, Deininger MW, Comparison of imatinib, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-n-nitrosourea (ENU)-based mutagenesis screen: High efficacy of drug combinations. Blood, 2006. 108(7): p. 2332-8.
• Bumm TG, Elsea C, Corbin AS, Loriaux M, Sherbenou D, Wood L, Deininger J, Silver RT, Druker BJ, Deininger MW, Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res, 2006. 66(23): p. 11156-65.
• OHare T, Eide CA, Deininger MW, Bcr-Abl kinase domain mutations, drug resistance and the road to a cure of chronic myeloid leukemia. Blood, 2007. May 11; [Epub ahead of print].
• Deininger MW, Cortes J, Paquette R, Park B, Hochhaus A, Baccarani M, Stone R, Fischer T, Kantarjian H, Niederwieser D, Gambacorti-Passerini C, So C, Gathmann I, Goldman JM, Smith D, Druker BJ, Guilhot F, The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer, 2007. Aug 14; [Epub ahead of print].

• Search PubMed for more publications